MDM2-Dependent Rewiring of Metabolomic and Lipidomic Profiles in Dedifferentiated Liposarcoma Models

MDM2-Dependent Rewiring of Metabolomic and Lipidomic Profiles in Dedifferentiated Liposarcoma Models

Dedifferentiated liposarcoma (DDLPS) is an aggressive mesenchymal cancer marked by amplification of MDM2, an inhibitor of the tumor suppressor TP53. DDLPS patients with higher MDM2 amplification have lower chemotherapy sensitivity and worse outcome than patients with lower MDM2 amplification. We hyp...

Full description

Bibliographic Details
Main Authors: Andrew Patt, Bryce Demoret, Colin Stets, Kate-Lynn Bill, Philip Smith, Anitha Vijay, Andrew Patterson, John Hays, Mindy Hoang, James L. Chen, Ewy A. Mathé
Format: Article
Language:English
Published: MDPI AG 2020-08-01
Series:Cancers
Subjects:
dedifferentiated liposarcoma (DDLPS)
metabolomics
lipidomics
MDM2
sphingolipid metabolism
atorvastatin
Online Access:https://www.mdpi.com/2072-6694/12/8/2157

Internet

https://www.mdpi.com/2072-6694/12/8/2157

Similar Items